Author

L. W. Huff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. M. Paulos· 2 shared H. M. Knochelmann· 2 shared M. H. Nelson· 2 shared M. M. Wyatt· 2 shared A. M. Rivera Reyes· 1 shared A. R. Medvec· 1 shared A. S. Smith· 1 shared G. B. Lesinski· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. M. Paulos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy

M. M. Wyatt, L. W. Huff, M. H. Nelson, L. R. Neal, A. R. Medvec, G. O. Rangel Rivera, A. S. Smith, A. M. Rivera Reyes, H. M. Knochelmann, J. L. Riley, G. B. Lesinski, C. M. Paulos

This study shows that reducing TCR and co-stimulation signal strength in Th17 cell manufacturing enhances their metabolic fitness and antitumor efficacy in mesothelioma models.

bioRxiv · Oct 28, 2022Immunology

Identification of human CD4+ T cell populations with distinct antitumor activity

M. H. Nelson, H. M. Knochelmann, S. R. Bailey, L. W. Huff, J. S. Bowers, K. Majchrzak, M. M. Wyatt, M. P. Rubinstein, S. Mehrotra, M. I. Nishimura, K. Armeson, P. G. Giresi, M. J. Zilliox, H. E. Broxmeyer, C. M. Paulos

The paper identifies human CD4+ T cell populations with distinct antitumor activity, showing CD26high T cells are epigenetically and transcriptionally different from Th17 cells and are more effective in tumor therapy.

bioRxiv · Dec 31, 2019Immunology